New two-sided antibody can get into the brain and target pathologic Alzheimer protein – with video! #science

scitransmedAn awesome new study published in Science Translational Medicine shows that a two-sided antibody could be an effective therapeutic for Alzheimers Disease. The brains of Alzheimers patients are riddled with pathological protein plaques and tangles. Removing the pathological protein from the brain using antibodies targeting them for degradation has long been thought to be a potential therapeutic. One major hurdle in implementing this, has been a mechanism to get the antibody into the brain. The brain is protected from the rest of the body by the blood brain barrier, making it harder to target with drugs and other large therapeutic agents. In this study, the authors have designed a two-sided antibody that can pass into the brain. One side of the antibody targets a protein in the brain that is responsible for making pathological amyloid. The other side of the antibody highjacks a receptor protein, which allows the antibody to enter the brain! The study shows that this antibody can be delivered intravenously in monkeys and reduce pathological protein in the brain!

Here is a link to a great cartoon video showing how this two-sided antibody works! Hopefully this technology can be used for other brain diseases, such as Parkinson’s disease, Amyotrophic Lateral Sclerosis, and more!genennature

‘Amazing’ results reported for new melanoma combination immuno-therapy


Another post from the 50th meeting of the American Society of Clinical Oncology (ASCO)(earlier post). Extremely promising results were shown for a new combination immunotherapy for melanoma (ipilimumab (Yervoy, Bristol-Myers Squibb), investigational antibody nivolumab (Bristol-Myers Squibb)). Melanoma has been a tricky, hard to treat cancer for researchers, so this small study is truly remarkable.

“Concurrent use of the 2 immune-checkpoint blockade agents has produced the “unprecedented” overall survival rates for metastatic melanoma of 85% at 1 year and 79% at 2 years in a phase 1 study, said lead author Mario Sznol, MD, from the Yale University School of Medicine in New Haven, Connecticut.

The median overall survival for the 53 patients treated in the study was 40 months — also unprecedented. “That’s amazing,” Dr. Sznol told Medscape Medical News.”


Medscape article here.

Summary and more findings.